4D Molecular Therapeutics Inc (4DMT) is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s pipeline products include 4D-125, 4D-110, 4D-150, 4D-175, 4D-310, 4D-725, and 4D-710. It has developed a technology platform, Therapeutic Vector Evolution, that facilitates the creation of customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. 4DMT develops pipeline products that target areas such as liver, retina, heart, brain, skeletal muscle, and lungs. The company works in partnership with F. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 4DMT is headquartered in Emeryville, California, the US.
Headquarters
United States of America
Address
5858 Horton Street #455, Emeryville, California, 94608
Website
4dmoleculartherapeutics.com
Telephone
1 510 5052680
No of Employees
147
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FDMT (NASD)
Revenue (2022)
$20.7M
562.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
6.2%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
85.8%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Retina: |
| Choroideremia (4D-110) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Arbor Biotechnologies to create six AAV-delivered CRISPR/Cas-based therapeutic candidates. |
| 2024 | Regulatory Approval | In January, the company received Rare Pediatric Disease Designation (RPDD) from U.S. Food and Drug Administration (FDA) for its product candidate aerosolized 4D-710 for the treatment of cystic fibrosis (CF) lung disease. |
| 2023 | Regulatory Approval | In December, the company received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet age-related macular degeneration (wet AMD). |
Competitor Comparison
| Key Parameters | 4D Molecular Therapeutics Inc | AbbVie Inc | Takeda Pharmaceutical Co Ltd | Regeneron Pharmaceuticals Inc | Vertex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Japan | United States of America | United States of America |
| City | Emeryville | North Chicago | Chuo-Ku | Tarrytown | Boston |
| State/Province | California | Illinois | Tokyo | New York | Massachusetts |
| No. of Employees | 147 | 50,000 | 49,095 | 13,450 | 5,400 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John F. Milligan, Ph.D. | Chairman | Executive Board | 2020 | 62 |
| David Kirn, M.D. | Chief Executive Officer; Director | Executive Board | 2013 | 61 |
| Fariborz Kamal, Ph.D. | President; Chief Operating Officer | Senior Management | 2022 | 60 |
| Robert Y. Kim, M.D | Chief Medical Officer | Senior Management | 2023 | 62 |
| Noriyuki Kasahara, M.D. | Chief Scientific Officer | Senior Management | 2024 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer